H

Tilos Therapeutics

Lexington, MA

Download Project Profile
Client Tilos Therapeutics
Project Relocation to 65 Hayden Ave
Type Office/R&D
SF 11,000
Industry Biotechnology, R&D
Timeframe May 2018 - Nov 2018
Architect Aamodt/Plumb Architects
CM Homer Contracting
Mina Jung, PM
View all details

An ideal opportunity for expansion

Tilos Pharmaceuticals' new headquarters located at Hayden Research Campus in Lexington MA, provided the square footage and was the ideal opportunity to fit out laboratory and offices specifically designed to meet their needs.

New offices, collaborative and conference areas and chemistry and tissue culture labs.

Providing project management from planning through modifications, and into relocation and support during operational start-up so Tilos can continue working on the treatment of cancer and autoimmune diseases with greater efficiency.

See more

About the project

Founded in 2016, Tilos Therapeutics rapidly outgrew the shared facilities at Lab Central, Cambridge MA. The new Headquarters located at Hayden Research Campus in Lexington MA, provided the square footage and was the ideal opportunity to fit out laboratory and offices specifically designed to meet their needs.

The project consisted of offices, collaborative and conference areas and Chemistry and Tissue Culture labs.

Hereva Consultants was hired as Project Manager to guide them through their first expansion, ensuring that our client’s needs were addressed, and the work stayed on target. We provided project management from planning through modifications, and into relocation and support during operational start-up.

About the client

Tilos Therapeutics is developing antibodies for the treatment of cancer, with additional early efforts in fibrosis and autoimmune diseases. Tilos is building on decades of work by its scientific founders in understanding the role of LAP-expressing cells in immune regulation to rapidly bring anti-LAP antibodies into clinical development.

Earlier this month Tilos was purchased by Merck. Dean Li, Senior Vice President of Discovery and Translational Medicine at Merck Research Laboratories, had this to say. “Tilos has developed a compelling portfolio of candidates that employ a novel approach to modulating the potent signaling molecule TGF beta by binding to latency-associated peptide, with potential applications across a range of disease indications.”

Get in touch with us today.

Let Hereva provide the dynamic leadership, technical knowledge, experience and services you need to create the ideal facility for your business goals.